Evidence map›Paper›PMID 21418181›Full record

ArticleBritish journal of haematology2011

Expression of blood group genes by mesenchymal stem cells.

Richard Schäfer, Martina Schnaidt, Roland A Klaffschenkel, Georg Siegel, Michael Schüle, Maria Anna Rädlein, Ursula Hermanutz-Klein, Miriam Ayturan, Marine Buadze, Christoph Gassner and 4 more

Open access · greenAbstract read
In one paragraph

Article in British journal of haematology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.3field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 29 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. ABO genotyping: the quest for clinical applications.Blood transfusion = Trasfusione del sangue · 2013
    Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 3 countries.

Richard SchäferInstitute of Clinical and Experimental Transfusion Medicine, University Hospital Tübingen, Tübingen, Germany.
Martina Schnaidt
Roland A Klaffschenkel
Georg Siegel
Michael Schüle
Maria Anna Rädlein
Ursula Hermanutz-Klein
Miriam Ayturan
Marine Buadze
Christoph Gassner
Lusine Danielyan
Torsten Kluba
Hinnak Northoff
Willy A Flegel
University Children's Hospital Tübingen · DEHarvard University · USNational Institutes of Health Clinical Center · USSwiss Red Cross · CH

Funding

Intramural NIH HHS Z99 CL999999
6 · The paper itself

Abstract

Incompatible blood group antigens are highly immunogenic and can cause graft rejections. Focusing on distinct carbohydrate- and protein-based membrane structures, defined by blood group antigens, we investigated human bone marrow-derived mesenchymal stem cells (MSCs) cultured in human serum. The presence of H (CD173), ABO, RhD, RhCE, RhAG, Kell, urea transporter type B (SLC14A1, previously known as JK), and Duffy antigen receptor of chemokines (DARC) was evaluated at the levels of genome, transcriptome and antigen. Fucosyltransferase-1 (FUT1), RHCE, KEL, SLC14A1 (JK) and DARC mRNA were transcribed in MSCs. FUT1 mRNA transcription was lost during differentiation. The mRNA transcription of SLC14A1 (JK) decreased during chondrogenic differentiation, while that of DARC increased during adipogenic differentiation. All MSCs synthesized SLC14A1 (JK) but no DARC protein. However, none of the protein antigens tested occurred on the surface, indicating a lack of associated protein function in the membrane. As A and B antigens are neither expressed nor adsorbed, concerns of ABO compatibility with human serum supplements during culture are alleviated. The H antigen expression by GD2dim+ MSCs identified two distinct MSC subpopulations and enabled their isolation. We hypothesize that GD2(dim+) H(+) MSCs retain a better 'stemness'. Because immunogenic blood group antigens are lacking, they cannot affect MSC engraftment in vivo, which is promising for clinical applications.

Indexed as

ABO Blood-Group SystemBlood Group AntigensCell DifferentiationCells, CulturedDuffy Blood-Group SystemErythrocytesGangliosidesHumansImmunophenotypingMembrane Transport ProteinsMesenchymal Stem CellsReceptors, Cell SurfaceRNA, MessengerTranscription, GeneticUrea TransportersABO Blood-Group SystemACKR1 protein, humanBlood Group AntigensDuffy Blood-Group Systemganglioside, GD2GangliosidesMembrane Transport ProteinsReceptors, Cell SurfaceRNA, MessengerUrea Transporters

Identifiers

PMID21418181
PMCPMC3080447
OpenAlexW1585554212

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.